Mirtazapine methods of identification suitable for the chemical and toxicological analysis. Development and study

S. Baiurka, S. Karpushyna, V. Bondar, V. Stepanenko, S. Poluyan, E. Pogosyan, V. Moroz

Abstract


Topicality. Mirtazapine is a thymoleptic used in pharmacotherapy for depressive disorders of different severe levels. Repeated cases of fatal mirtazapine poisonings have been reported. Development of available and reliable methods for the chemical and toxicological analysis of mirtazapine is an actual task.

Aim. The main goal of our scientific research is to develop conditions for mirtazapine detection when performing general TLC-screening and the antidepressant identification by UV spectrophotometry.

Materials and methods. Chromatographic mirtazapine mobility in thin sorbent layers has been studied in 17 mobile phases and including those recommended by TIAFT, using four types of chromatographic plates. A number of chromogenic reagents have been examined for visualization. UV spectrum of mirtazapine has been studied in hydrochloric acid solution with concentration of 0.1 mol∙L-1.

Results and discussion. Chromatographic systems with low hRf  correlation for mirtazapine were found and they are suitable for general toxicological screening. In acidic solution UV spectrum of mirtazapine had light absorption maxima at 253, 273 and 316 nm wavelength.

Conclusions. Combined use of mobile phases: ethyl acetate – methanol – 25 % ammonia solution (85:10:5), methanol – 25% ammonia solution (100 : 1.5), cyclohexane – toluene– diethylamine (75 : 15 : 10) provides reliable detection of mirtazapine when performing TLC screening. The presence of specific light absorption in the UV region of  spectrum for mirtazapine has been established.


Keywords


mirtazapine; thin layer chromatography; UV-spectrum

References


Mashkovskii, M. D. (2012). Lekarstvennye sredstva.Moscow: Novaia Volna, 112.

Anttila, S. A. K., Leinonen, E. V. J. (2006). A Review of the Pharmacological and Clinical Profile of Mirtazapine. CNS Drug Reviews, 7 (3), 249–264. doi: 10.1111/j.1527–3458.2001.tb00198.x

Drobizhev, M. Yu., Kikta, S. V. (2009). Sotcialnaia i kliicheskaiia. Psikhiatriia, 3, 60–65.

Pavlichenko, A. V. (2010). Effektivnaia farmakoterapiia v nevrologii i psikhiatrii, 3, 16–20.

Behnke, K., Sogaard, J., Martin, S. et al. (2003). Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study. Journal of Clinical Psychopharmacology, 23 (4), 358–364. doi: 10.1097/01.jcp.0000085408.08426.05

Malin, D. I., Yankin, E. V., Medvedev, V. M. (2003). Psikhiatriia i psikhofarmakoterapiia, 5 (3), 113–115.

Graves, S. M., Rafeyan, R., Watts, J., Napier, T. C. (2012). Mirtazapine, and mirtazapine–like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside. Pharmacology & Therapeutics, 136 (3), 343–353. doi: 10.1016/j.pharmthera.2012.08.013

Wenzel, S., Aderjan, R., Mattern, R., Pedal, I., Skopp, G. (2006). Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning. Forensic Science International, 156 (2–3), 229–236. doi: 10.1016/j.forsciint.2005.06.007

Anderson, D. T., Fritz, K. L., Muto, J. J. (1999). Distribution of Mirtazapine (Remeron(R)) in Thirteen Postmortem Cases. Journal of Analytical Toxicology, 23 (6), 544–548. doi: 10.1093/jat/23.6.544

Moore, K. A., Levine, B., Smith, M. L., Saki, S., Schames, J., Smialek, J. E. (1999). Tissue Distribution of Mirtazapine (Remeron(R)) in Postmortem Cases. Journal of Analytical Toxicology, 23 (6), 541–543. doi: 10.1093/jat/23.6.541

Baselt, C. R. (2011). Disposition of Toxic Drugs and Chemicals in Man: 9–th edition. Seal Beach, California: Biomedical Publications, 1900.

Moffat, A. C., Osselton, M. D., Widdop, B., Ed. (2011). Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material: 4–th edition. London, Chicago: Pharmaceutical Press, 2736.

Hong, X., Yao, Y., Hong, S., Lei, C. (2008). LC–MS–MS Analysis of Mirtazapine in Plasma, and Determination of Pharmacokinetic Data for Rats. Chromatographia, 68 (1–2), 65–70. doi: 10.1365/s10337–008–0656–9

Mandrioli, R., Mercolini, L., Ghedini, N., Bartoletti, C., Fanali, S., Raggi, M. A. (2006). Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection. Analytica Chimica Acta, 556 (2), 281–288. doi: 10.1016/j.aca.2005.09.049

Malfará, W. R., Bertucci, C., Costa Queiroz, M. E., Dreossi Carvalho, S. A., de Lourdes Pires Bianchi, M., Cesarino, E. J., Costa Queiroz, R. H. (2007). Reliable HPLC method for therapeutic drug monitoring of frequently prescribed tricyclic and nontricyclic antidepressants. Journal of Pharmaceutical and Biomedical Analysis, 44 (4), 955–962. doi: 10.1016/j.jpba.2007.04.005

Sánchez de la Torre, C., Martínez, M. A., Almarza, E. (2005). Determination of several psychiatric drugs in whole blood using capillary gas–liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures. Forensic Science International, 155 (2–3), 193–204. doi: 10.1016/j.forsciint.2004.12.007

Wille, S. M. R., De Letter, E. A., Piette, M. H. A., Van Overschelde, L. K., Van Peteghem, C. H., Lambert, W. E. (2008). Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography–mass spectrometry. International Journal of Legal Medicine, 123 (6), 451–458. doi: 10.1007/s00414–008–0287–6

Mandrioli, R., Pucci, V., Sabbioni, C., Bartoletti, C., Fanali, S., Raggi, M. A. (2004). Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis. Journal of Chromatography A, 1051 (1–2), 253–260. doi: 10.1016/j.chroma.2004.05.020

Jickells, S., Negrusz, A., Ed. (2008). Clarke’s Analytical Forensic Toxicology. London: Pharmaceutical Press, 648.

Khizhnichenko, O. V., Huzenko, N. V., Chubenko, O. V. (2011). Farmatsevtychnyi zhurnal, 6, 74–78.

Rapid Testing Methods of Drugs of Abuse: Manual for Use by National Law Enforcement and Narcotic Laboratory Personnel. (2008). Published by United Nations, Bernan Press, 111.

Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens (United Nations Office on Drugs and Crime, Vienna). (2009). New York, 67.


GOST Style Citations


1.         Машковский, М. Д. Лекарственные средства : 16–е изд., перераб., испр. и доп. / М. Д. Машковский. – М. : Новая Волна, 2012. – 112 с.

2.         Anttila, S. A. A review of the pharmacological and clinical profile of mirtazapine / S. A. Anttila, E. V. Leinonen // CNS Drug Rev. – 2006. – Vol. 7, Issue 3. – P. 249–264. doi: 10.1111/j.1527–3458.2001.tb00198.x

3.         Дробижев, М. Ю. Как использовать Миртазапин в клинической практике? / М. Ю. Дробижев, С. В. Кикта // Соц. и клин. психиатрия. – 2009. – № 3. – С. 60–65.

4.         Павличенко, А. В. Клинические особенности применения миртазапина (Миртазонала) / А. В. Павличенко // Эффективная фармакотерапия в неврол. и психиатрии. – 2010. – № 3. – С. 16–20.

5.         Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study / K. Behnke, J. Sogaard, S. Martin et al. // J. Clin. Psychopharm. – 2003. – Vol. 23, Issue 4. – P. 358–364. doi: 10.1097/01.jcp.0000085408.08426.05

6.         Maлин, Д. И. Эффективность ремерона в комплексной терапии алкогольного абстинентного синдрома / Д. И. Maлин, Е. В. Янкин, В. М. Медведев // Психиатрия и психофармакотерапия. – 2003. – Т. 5, № 3. – С. 113–115.

7.         Mirtazapine, and mirtazapine–like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside / S. M. Graves, R. Rafeyan, J. Watts et al. // Pharmacol. Ther. – 2012. – Vol. 136, Issue 3. – P. 343–353. doi: 10.1016/j.pharmthera.2012.08.013

8.         Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning / S. Wenzel, R. Aderjan, R. Mattern et al. // Forensic Sci. Int. – 2006. – Vol. 156, Issue 2–3. – P. 229–236. doi: 10.1016/j.forsciint.2005.06.007

9.         Anderson, D. T. Distribution of mirtazapine (Remeron) in thirteen postmortem cases / D. T. Anderson, K. L. Fritz, J. J. Muto // J. Anal. Toxicol. – 1999. – Vol. 23, Issue 6. – P. 544–548. doi: 10.1093/jat/23.6.544

10.       Tissue distribution of mirtazapine (Remeron) in postmortem cases / K. A. Moore, B. Levine, M. L. Smith et al. // J. Anal. Toxicol. – 1999. – Vol. 23, Issue 6. – P. 541–543. doi: 10.1093/jat/23.6.541

11.       Baselt, C. R. Disposition of Toxic Drugs and Chemicals in Man : 9–th ed. / C. R. Baselt. – Seal Beach, California : Biomedical Publications, 2011. – 1900 p.

12.       Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material : 4–th ed. / Ed. by A. C. Moffat, M. D. Osselton, B. Widdop. – London, Chicago : Pharmaceutical Press, 2011. – 2736 p.

13.       LC–MS–MS analysis of mirtazapine in plasma, and determination of pharmacokinetic data for rats / X. Hong, Y. Yao, S. Hong, C. Lei // Chromatographia. – 2008. – Vol. 68, Issue 1–2. – P. 65–70. doi: 10.1365/s10337–008–0656–9

14.       Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection / R. Mandrioli, L. Mercolini, N. Ghedini et al. // Anal. Chim. Acta. – 2006. – Vol. 556, Issue 2. – P. 281–288. doi: 10.1016/j.aca.2005.09.049

15.       Reliable HPLC method for therapeutic drug monitoring of frequently prescribed tricyclic and nontricyclic antidepressants / W. R. Malfara, C. Bertucci, M. E. Cost Queiroz et al. // J. Pharm. Biomed. Anal. – 2007. – Vol. 44, Issue 4. – P. 955–962. doi: 10.1016/j.jpba.2007.04.005

16.       Sánchez de la Torre, C. Determination of several psychiatric drugs in whole blood using capillary gas–liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures / C. Sánchez de la Torre, M. A. Martínez, E. Almarza // Forensic Sci. Int. – 2005. – Vol. 155, Issue 2–3. – P. 193–204. doi: 10.1016/j.forsciint.2004.12.007

17.       Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography–mass spectrometry / S. M. Wille, E. A. De Letter, M. H. Piette et al. // Int. J. Legal Med. – 2008. – Vol. 123, Issue 6. – P. 451–458. doi: 10.1007/s00414–008–0287–6

18.       Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis / R. Mandrioli, V. Pucci, C. Sabbioni et al. // J. Chromatogr. A. – 2004. – Vol. 1051, Issue 1–2. – P. 253–260. doi: 10.1016/j.chroma.2004.05.020

19.       Clarke’s Analytical Forensic Toxicology / ed. by Sue Jickells, Adam Negrusz. – London : Pharmaceutical Press, 2008. – 648 p.

20.       Хіжніченко, О. В. Хіміко–токсикологічне дослідження нових лікарських засобів – потенційних об’єктів немедичного використання методом хроматографії у тонких шарах сорбенту / О. В. Хіжніченко, Н. В. Гузенко, О. В. Чубенко // Фармац. журн. – 2011. – Вип. 6. – С. 74–78.

21.       Rapid Testing Methods of Drugs of Abuse : Manual for Use by National Law Enforcement and Narcotic Laboratory Personnel. – Published by United Nations, Bernan Press, 2008. – 111 p.

22.       Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens (United Nations Office on Drugs and Crime, Vienna). – New York, 2009. – 67 p.





DOI: https://doi.org/10.24959/ubphj.17.109

Abbreviated key title: Ukr. bìofarm. ž.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)